Placebo News and Research

RSS

Promising early results in a study of a medication to treat kleptomania

Kleptomania, the guilt-ridden, impulsive stealing of inexpensive and unneeded items, often goes untreated as many who suffer from the disorder hesitate to seek help out of fear of being turned in for their illegal activities.

23 Sep 2004

FDA proposal on antidepressants is premature and may be counterproductive

The recent FDA proposal to force antidepressants to carry warnings about increased suicide risk is the subject of a pair of articles by leading experts in The Annals of Pharmacotherapy.

23 Sep 2004

Acupuncture more effective at reducing nausea and vomiting after major breast surgery than the leading medication

The researchers also found that patients who underwent the 5,000-year-old Chinese practice reported decreased postoperative pain and increased satisfaction with their postoperative recovery. In conducting the trial, the researchers also demonstrated that the pressure point they stimulated possesses previously unknown pain-killing properties.

22 Sep 2004

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Scientists at Dana-Farber Cancer Institute and Brigham and Women's Hospital have prolonged the lives of mice with a rare blood disorder by using an experimental drug that blocks signals promoting runaway growth of blood cells.

21 Sep 2004

New gene therapy technique may help treat Alzheimer's disease

Investigators at Rush University Medical Center have successfully initiated a new technique that uses gene therapy to deliver nerve growth factor into regions of the brain where neurons are degenerating, in order to prevent cell death and reverse cell atrophy, two hallmarks of Alzheimer's disease.

21 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

European positive for Cymbalta and Xeristar

Eli Lilly and Company and Boehringer Ingelheim have announced that the Committee for Medicinal Products in Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending approval of duloxetine for the treatment of major depressive episodes.

20 Sep 2004

Immunoglobulins may help patients with Alzheimer’s

Immunoglobulins which are already being used to treat multiple sclerosis may also be able to help patients with Alzheimer’s. This, at least, is the finding of a pilot study on five patients at the University of Bonn.

20 Sep 2004

Botox injections may ease the irritation of tinnitus

A preliminary study indicates that Botox injections may ease the irritation of tinnitus, otherwise know as ringing in the ears, for some patients. Researchers say more study is needed, but initial results are promising.

18 Sep 2004

Israeli clinicians keen on using placebos in treating patients

Three out of five Israeli clinicians report using placebos – inactive treatments or drugs – in treating patients, despite the medical profession's official disapproval of their use, say the authors of a BMJ Online First paper this week.

17 Sep 2004

Wyeth supports FDA recommendation to strengthen antidepressant labeling

Statement by Wyeth Pharmaceuticals supporting the U.S. Food and Drug Administration (FDA) Joint Advisory Committee’s recommendation to strengthen the product labels across the antidepressant category regarding use in the pediatric population.

16 Sep 2004

Celacade shown to reduce risk of death and hospitalization in patients with advanced chronic heart failure

Vasogen has announced that comprehensive results from the Company's phase II trial of Celacade (immune modulation therapy) in advanced chronic heart failure patients were published in the September 15 issue of the Journal of the American College of Cardiology (JACC).

16 Sep 2004

Treatment with vitamin A and an omega-3 fatty acid slows down the progression of retinitis pigmentosa

Patients with retinitis pigmentosa, a progressive eye disease that can cause vision loss, who were treated with vitamin A and docosahexaenoic acid (DHA), a kind of omega-3 fatty acid, did not experience slowing of the progression of their disease

12 Sep 2004

Cancer drug may reduce kidney disease in lupus

A drug that is already being tested as an anticancer agent, especially in lymphoma, may also reduce the kidney disease that is a result of systemic lupus, according to a researcher at Wake Forest University Baptist Medical Center.

10 Sep 2004

Phase I clinical trial of new drug for severe asthma

Cambridge Antibody Technology today announced that it is starting a Phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

8 Sep 2004

Cymbalta approved for diabetic peripheral neuropathy pain

The U.S. Food and Drug Administration has approved Eli Lilly's Cymbalta, a balanced and potent serotonin and norepinephrine reuptake inhibitor. Cymbalta is the first and only FDA-approved treatment for pain caused by diabetic peripheral neuropathy.

8 Sep 2004

The drug galantamine has been shown to be ineffective in treating chronic fatigue syndrome

The drug galantamine (used for treatment of mild to moderate dementia) did not demonstrate a clinical benefit in treating chronic fatigue syndrome when compared with placebo, according to a study in the September 8 issue of JAMA.

8 Sep 2004

Ramipril reduces rate of sudden cardiac death and nonfatal cardiac arrest by 21 percent

Ramipril, a high blood pressure and heart failure drug, can reduce the rate of sudden cardiac death and nonfatal cardiac arrest by 21 percent in people at high risk for heart attack or stroke, according to a study reported in Circulation: Journal of the American Heart Association.

7 Sep 2004

Sinovac completes dosing in phase 1 human clinical testing of SARS vaccine

Sinovac Biotech Ltd. has announced that all 36 subjects of the Phase I human clinical trial for its inactivated SARS vaccine have now been vaccinated with two doses of either SARS vaccine or placebo.

7 Sep 2004

Topiramate help patients with alcohol dependence

The drug topiramate helps reduce drinking and improves overall quality of life among patients with alcohol dependence, according to an article in the September issue of the Archives of General Psychiatry.

7 Sep 2004